1
|
Deeken JF, Cormier T, Price DK, Sissung TM, Steinberg SM, Tran K, Liewehr DJ, Dahut WL, Miao X, Figg WD. A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform. Pharmacogenomics J 2010; 10:191-9. [PMID: 20038957 PMCID: PMC6631360 DOI: 10.1038/tpj.2009.57] [Citation(s) in RCA: 56] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/24/2008] [Revised: 10/16/2009] [Accepted: 11/01/2009] [Indexed: 01/11/2023]
Abstract
The anticancer agent docetaxel shows significant inter-individual variation in its pharmacokinetic and toxicity profile. Thalidomide is an active anticancer agent and also shows wide pharmacological variation. Past pharmacogenetic research has not explained this variation. Patients with prostate cancer enrolled in a randomized phase II trial using docetaxel and thalidomide versus docetaxel alone were genotyped using the Affymetrix DMET 1.0 platform, which tests for 1256 genetic variations in 170 drug disposition genes. Genetic polymorphisms were analyzed for associations with clinical response and toxicity. In all, 10 single-nucleotide polymorphisms (SNPs) in three genes were potentially associated with response to therapy: peroxisome proliferator-activated receptor-delta (PPAR-delta), sulfotransferase family, cytosolic, 1C, member 2 (SULT1C2) and carbohydrate (chondroitin 6) sulfotransferase 3 (CHST3). In addition, 11 SNPs in eight genes were associated with toxicities to treatment: spastic paraplegia 7 (pure and complicated autosomal recessive) (SPG7), CHST3, cytochrome P450, family 2, subfamily D, polypeptide 6 (CYP2D6), N-acetyltransferase 2 (arylamine N-acetyltransferase) (NAT2), ATP-binding cassette, sub-family C (CFTR/MRP), member 6 (ABCC6), ATPase, Cu++ transporting, alpha polypeptide (ATP7A), cytochrome P450, family 4, subfamily B, polypeptide 1 (CYP4B1) and solute carrier family 10 (sodium/bile acid cotransporter family), member 2 (SLC10A2). Genotyping results between drug metabolizing enzymes and transporters (DMET) and direct sequencing showed >96% of concordance. These findings highlight the role that non-CYP450 metabolizing enzymes and transporters may have in the pharmacology of docetaxel and thalidomide.
Collapse
Affiliation(s)
- J F Deeken
- Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
2
|
Deeken JF, Cormier T, Price DK, Steinberg S, Tran K, Liewehr DJ, Ockers SB, Hardenbol P, Dahut W, Miao X, Figg WD. A pharmacogenetic study of docetaxel and thalidomide in patients with androgen-independent prostate cancer (AIPC) using targeted human DMET genotyping platform. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.3580] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
3580 Background: Pharmacogenetic research holds the promise of individualizing cancer therapy by reducing inter-individual variability in drug response, thus enhancing efficacy and reducing toxicity. Past research has been limited due to the lack of a robust genotyping platform that can screen for single nucleotide polymorphisms (SNPs) in the dozens of genes known to be involved in drug disposition. We pilot tested the new Affymetrix Targeted Human Drug Metabolizing Enzymes and Transporter (DMET) 1.0 panel in an exploratory study of docetaxel and thalidomide. The DMET 1.0 panel tests for 1,229 genetic variations in 169 drug disposition genes, including 49 CYP450 genes, 73 non-CYP genes, and 47 transporters. Methods: DNA samples from 47 patients with AIPC enrolled in a randomized phase II trial using docetaxel and thalidomide vs. docetaxel alone were genotyped using the DMET 1.0 panel. Patients’ response was determined using RECIST criteria. Toxicities were graded using the NCI-CTC, and patients were identified if they experienced grade 3 or 4 toxicity. Given the distinct side effect profiles of these two drugs, specific toxicities were assigned as being due to either docetaxel or thalidomide. An association between the SNP parameters and clinical response or toxicity was tested using Mehta’s modification to Fisher’s exact test. Reported results were limited to those where p<0.01. Results: Six SNPs in three genes were associated with response to therapy: PPAR-delta (p=0.0011), SULT1C2 (p=0.0083), and CHST3 (4 SNPs, p=0.0001 to 0.0034). For toxicities associated with docetaxel, five SNPs in three genes were identified: UGT1A1 (2 SNPs, p=0.0009 to 0.0094), UGT1A9 (2 SNPs, p=0.0016 to 0.0096), and CYP2A7 (p=0.0027). SNPs in CYP2B6 (p=0.0033), ABCC1 (p=0.0036), and ABCC6 (p=0.0075) were associated with toxicities from thalidomide. Conclusion: We identified nine genes in which SNPs were potentially significantly associated with clinical response and toxicity to treatment. These results highlight the important role that non-CYP450 and phase II drug metabolizing enzymes may play in the efficacy and disposition of docetaxel and thalidomide. Confirmatory studies are warranted. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- J. F. Deeken
- National Cancer Institute, Bethesda, MD; Affymetrix Inc, South San Francisco, CA
| | - T. Cormier
- National Cancer Institute, Bethesda, MD; Affymetrix Inc, South San Francisco, CA
| | - D. K. Price
- National Cancer Institute, Bethesda, MD; Affymetrix Inc, South San Francisco, CA
| | - S. Steinberg
- National Cancer Institute, Bethesda, MD; Affymetrix Inc, South San Francisco, CA
| | - K. Tran
- National Cancer Institute, Bethesda, MD; Affymetrix Inc, South San Francisco, CA
| | - D. J. Liewehr
- National Cancer Institute, Bethesda, MD; Affymetrix Inc, South San Francisco, CA
| | - S. B. Ockers
- National Cancer Institute, Bethesda, MD; Affymetrix Inc, South San Francisco, CA
| | - P. Hardenbol
- National Cancer Institute, Bethesda, MD; Affymetrix Inc, South San Francisco, CA
| | - W. Dahut
- National Cancer Institute, Bethesda, MD; Affymetrix Inc, South San Francisco, CA
| | - X. Miao
- National Cancer Institute, Bethesda, MD; Affymetrix Inc, South San Francisco, CA
| | - W. D. Figg
- National Cancer Institute, Bethesda, MD; Affymetrix Inc, South San Francisco, CA
| |
Collapse
|
3
|
Prakash SK, Gibson CW, Wright JT, Boyd C, Cormier T, Sierra R, Li Y, Abrams WR, Aragon MA, Yuan ZA, van den Veyver IB. Tooth enamel defects in mice with a deletion at the Arhgap 6/Amel X locus. Calcif Tissue Int 2005; 77:23-9. [PMID: 16007484 DOI: 10.1007/s00223-004-1213-7] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/05/2004] [Accepted: 02/01/2005] [Indexed: 11/27/2022]
Abstract
The amelogenin proteins regulate enamel mineral formation in the developing tooth. The human AMELX gene, which encodes the amelogenin proteins, is located within an intron of the Arhgap 6 gene. ARHGAP 6 encodes a Rho GAP, which regulates activity of Rho A, a small G protein involved in intracellular signal transduction. Mice were generated in which the entire ARHGAP 6 gene was deleted by Cre-mediated recombination, which also removed the nested Amel X gene. Enamel from these mice appeared chalky white, and the molars showed excessive wear. The enamel layer was hypoplastic and non-prismatic, whereas other dental tissues had normal morphology. This phenotype is similar to that reported for Amel X null mice, which have a short deletion that removed the region surrounding the translation initiation site, and resembles some forms of X-linked amelogenesis imperfecta in humans. Analysis of the enamel from the Arhgap 6/Amel X-deleted mice verifies that the Amel X gene is nested within the murine Arhgap 6 gene and shows that removal of the entire Amel X gene leads to a phenotype similar to the earlier Amel X null mouse results, in which no amelogenin protein was detected. However, an unusual layer of aprismatic enamel covers the enamel surface, which may be related to the 1.1-Mb deletion, which included Arhgap 6 in these mice.
Collapse
Affiliation(s)
- S K Prakash
- Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Barrette J, Bellwied R, Braun-Munzinger P, Cleland WE, Cormier T, Dadusc G, David G, Dee J, Dietzsch O, Fatyga M, Greene SV, Germani JV, Hall JR, Hemmick TK, Herrmann N, Hogue RW, Hong B, Jayananda K, Kraus D, Kumar BS, Lacasse R, Lissauer D, Llope WJ, Ludlam TW, Majka R, Mark SK, Mitchell JT, Muthuswamy M, O'Brien E, Pruneau C, Rotondo FS, Simon-Gillo J, Sonnadara U, Stachel J, Takai H, Takagui EM, Throwe TG, Waters L, Winter C, Wolfe D, Woody CL, Xu N, Zhang Y, Zhang Z, Zou C. Search for pion-neutron bound states in 14.6A GeV Si + nucleus collisions. Phys Rev C Nucl Phys 1995; 52:2679-2683. [PMID: 9970798 DOI: 10.1103/physrevc.52.2679] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/22/2023]
|
5
|
Barrette J, Bellwied R, Braun-Munzinger P, Cleland WE, Cormier T, David G, Dee J, Diebold GE, Dietzsch O, Germani JV, Gilbert S, Greene SV, Hall JR, Hemmick TK, Herrmann N, Hong B, Jayananda K, Kraus D, Kumar BS, Lacasse R, Lissauer D, Llope WJ, Ludlam T, Majka R, Mark SK, Mitchell JT, Muthuswamy M, O'Brien E, Pruneau C, Rosati M, Rotondo FS, Sonnadara U, Stachel J, Takai H, Takagui EM, Wang G, Woody CL, Xu N, Zhang Y, Zhang Z, Zou C. Tranverse energy and charged particle multiplicity in p-nucleus collisions at 14.6 GeV/c. Phys Rev C Nucl Phys 1995; 52:2028-2036. [PMID: 9970719 DOI: 10.1103/physrevc.52.2028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/22/2023]
|
6
|
Barrette J, Bellwied R, Braun-Munzinger P, Cleland WE, Cormier T, Dadusc G, David G, Dee J, Diebold GE, Dietzsch O, Duek E, Fatyga M, Fox D, Greene SV, Germani JV, Hall JR, Hemmick TK, Herrmann N, Hogue RW, Hong B, Jayananda K, Kraus D, Kumar BS, Lacasse R, Lissauer D, Llope WJ, Ludlam TW, Majka R, Makowiecki D, Mark SK, Mitchell JT, Muthuswamy M, O'Brien E, Pruneau C, Rotondo FS, Sandweiss J, Simon-Gillo J, Slaughter J, Sonnadara U, Stachel J, Takai H, Takagui EM, Throwe TG, Waters L, Winter C, Wolf K, Wolfe D, Woody CL, Xu N, Zhang Y, Zhang Z, Zou C. Antiproton production in relativistic Si-nucleus collisions. Phys Rev Lett 1993; 70:1763-1766. [PMID: 10053380 DOI: 10.1103/physrevlett.70.1763] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
|